Anna Halliday
Research Subjects
Anna Halliday has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Chris Graham
RTI Health Solutions, Research Triangle Park, NC, USA
2 shared publicationsHelena Marzo-Ortega
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
2 shared publications- LaStella Miles
RTI Health Solutions, Research Triangle Park, North Carolina
2 shared publications Praveen Gunda
Novartis Healthcare Private Limited, Hyderabad, India
2 shared publicationsSteffen Marc Jugl
Novartis Pharma AG, Basel, Switzerland
2 shared publications- Alan Brennan
Sheffield Centre for Health and Related Research (SCHARR), School of Medicine and Population Health, University of Sheffield, Sheffield, UK
1 shared publication
Latest Publications
- Open Access
- 8 October 2020
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (4) , 928-937
Twelve‐week secukinumab treatment is consistently efficacious for moderate‐to‐severe psoriasis regardless of prior biologic and non‐biologic systemic treatment: Post hoc analysis of six randomised trials
Background: The efficacy of biologic therapies is greater among biologic‐naïve vs. biologic‐experienced psoriasis patients. However, little is known as to whether prior use of other systemic therapies impacts secukinumab efficacy in patients with moderate‐to‐severe psoriasis.Objective: To investigate the impact of prior exposure to systemic therapies upon the efficacy and safety of secukinumab 300 mg for moderate‐to‐severe psoriasis.Methods: Post hoc analysis of six randomised controlled trials (RCTs) comparing secukinumab with placebo, ustekinumab or etanercept at 12 weeks of treatment. Data comparing secukinumab with placebo and ustekinumab were meta‐analysed, while comparisons between secukinumab and etanercept were from a single RCT. Four subgroups of patients were assessed: (i) naïve to non‐biologic systemics (NBS) and biologics; (ii) exposed to NBS but naïve to biologics; (iii) naïve to NBS but exposed to biologics; and (iv) exposed to NBS and biologics. Outcomes of interest included the following: investigator’s global assessment (IGA) score, absolute psoriasis area and severity index (PASI) response, PASI 75, PASI 90 and PASI 100 responses, and dermatology life quality index (DLQI). Safety was also assessed.Results: One thousand three hundred and eighty‐three patients were included in the secukinumab vs. placebo meta‐analysis: 1776 in the secukinumab vs. ustekinumab meta‐analysis and 653 in the within‐trial analyses of secukinumab vs. etanercept. For all subgroups, secukinumab was significantly more efficacious than placebo for all outcomes measured. Secukinumab generated greater responses in biologic‐naïve patients, while prior NBS had a negligible impact on treatment response. Furthermore, secukinumab was more efficacious than both ustekinumab and etanercept on many outcomes, with an even greater difference for biologic‐naïve than biologic‐exposed patients. Safety results were consistent with individual clinical trial results.Conclusions: Twelve‐week treatment with secukinumab 300 mg is consistently more efficacious than placebo, etanercept and ustekinumab in patients with moderate‐to‐severe psoriasis, regardless of prior exposure to biologics or NBS. Secukinumab had a comparable safety profile to both etanercept and ustekinumab.
- 8 October 2020
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (4) , 928-937
Open AccessTwelve‐week secukinumab treatment is consistently efficacious for moderate‐to‐severe psoriasis regardless of prior biologic and non‐biologic systemic treatment: Post hoc analysis of six randomised trials
Background: The efficacy of biologic therapies is greater among biologic‐naïve vs. biologic‐experienced psoriasis patients. However, little is known as to whether prior use of other systemic therapies impacts secukinumab efficacy in patients with moderate‐to‐severe psoriasis.Objective: To investigate the impact of prior exposure to systemic therapies upon the efficacy and safety of secukinumab 300 mg for moderate‐to‐severe psoriasis.Methods: Post hoc analysis of six randomised controlled trials (RCTs) comparing secukinumab with placebo, ustekinumab or etanercept at 12 weeks of treatment. Data comparing secukinumab with placebo and ustekinumab were meta‐analysed, while comparisons between secukinumab and etanercept were from a single RCT. Four subgroups of patients were assessed: (i) naïve to non‐biologic systemics (NBS) and biologics; (ii) exposed to NBS but naïve to biologics; (iii) naïve to NBS but exposed to biologics; and (iv) exposed to NBS and biologics. Outcomes of interest included the following: investigator’s global assessment (IGA) score, absolute psoriasis area and severity index (PASI) response, PASI 75, PASI 90 and PASI 100 responses, and dermatology life quality index (DLQI). Safety was also assessed.Results: One thousand three hundred and eighty‐three patients were included in the secukinumab vs. placebo meta‐analysis: 1776 in the secukinumab vs. ustekinumab meta‐analysis and 653 in the within‐trial analyses of secukinumab vs. etanercept. For all subgroups, secukinumab was significantly more efficacious than placebo for all outcomes measured. Secukinumab generated greater responses in biologic‐naïve patients, while prior NBS had a negligible impact on treatment response. Furthermore, secukinumab was more efficacious than both ustekinumab and etanercept on many outcomes, with an even greater difference for biologic‐naïve than biologic‐exposed patients. Safety results were consistent with individual clinical trial results.Conclusions: Twelve‐week treatment with secukinumab 300 mg is consistently more efficacious than placebo, etanercept and ustekinumab in patients with moderate‐to‐severe psoriasis, regardless of prior exposure to biologics or NBS. Secukinumab had a comparable safety profile to both etanercept and ustekinumab.
- Open Access
- 25 May 2018
- Published by Springer Nature in PharmacoEconomics
- Vol. 36 (8) , 1015-1027
Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK
Objective To determine the cost effectiveness of secukinumab, a fully human interleukin-17A inhibitor, for adults in the UK with active ankylosing spondylitis (AS) who have not responded adequately to previous treatment with conventional care (CC; biologic-naïve population) or previous biologic therapy (biologic-experienced population). Perspective and Setting UK National Health Service (NHS). Methods The model was structured as a 3-month decision tree leading into a Markov model. Comparators were licensed tumour necrosis factor inhibitors (including available biosimilars) and CC in the biologic-naïve and biologic-experienced populations, respectively. Clinical parameters captured treatment response, short-term disease activity and patient functioning, as well as long-term structural disease progression. Utilities were derived from secukinumab trial data. List prices were used for all drugs. The cost year was 2017 and costs and outcomes were discounted at 3.5%. Results In the biologic-naïve population, secukinumab dominated adalimumab and certolizumab pegol. Incremental cost-effectiveness ratios (ICERs) versus other comparators were either below £10,000 per quality-adjusted life-year (QALY) gained or south-west ICERs that implied cost effectiveness of secukinumab. In biologic-experienced patients, the ICER for secukinumab versus CC was £4927 per QALY gained. Treatment response rates, short-term treatment effects, long-term radiographic progression and biologic acquisition costs were key model drivers. Scenario analysis found results to be robust to changes in model structural assumptions. Probabilistic analysis identified greater uncertainty in results in the biologic-naïve population. Conclusions Even at list price, secukinumab appears to represent a cost-effective use of NHS resources for biologic-naïve and biologic-experienced patients with active AS. Further research on long-term radiographic progression outcomes would be valuable for future cost-effectiveness analyses in AS.
- 25 May 2018
- Published by Springer Nature in PharmacoEconomics
- Vol. 36 (8) , 1015-1027
Open AccessCost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK
Objective To determine the cost effectiveness of secukinumab, a fully human interleukin-17A inhibitor, for adults in the UK with active ankylosing spondylitis (AS) who have not responded adequately to previous treatment with conventional care (CC; biologic-naïve population) or previous biologic therapy (biologic-experienced population). Perspective and Setting UK National Health Service (NHS). Methods The model was structured as a 3-month decision tree leading into a Markov model. Comparators were licensed tumour necrosis factor inhibitors (including available biosimilars) and CC in the biologic-naïve and biologic-experienced populations, respectively. Clinical parameters captured treatment response, short-term disease activity and patient functioning, as well as long-term structural disease progression. Utilities were derived from secukinumab trial data. List prices were used for all drugs. The cost year was 2017 and costs and outcomes were discounted at 3.5%. Results In the biologic-naïve population, secukinumab dominated adalimumab and certolizumab pegol. Incremental cost-effectiveness ratios (ICERs) versus other comparators were either below £10,000 per quality-adjusted life-year (QALY) gained or south-west ICERs that implied cost effectiveness of secukinumab. In biologic-experienced patients, the ICER for secukinumab versus CC was £4927 per QALY gained. Treatment response rates, short-term treatment effects, long-term radiographic progression and biologic acquisition costs were key model drivers. Scenario analysis found results to be robust to changes in model structural assumptions. Probabilistic analysis identified greater uncertainty in results in the biologic-naïve population. Conclusions Even at list price, secukinumab appears to represent a cost-effective use of NHS resources for biologic-naïve and biologic-experienced patients with active AS. Further research on long-term radiographic progression outcomes would be valuable for future cost-effectiveness analyses in AS.
- Open Access
- 25 May 2018
- Published by Springer Nature in PharmacoEconomics
- Vol. 36 (7) , 867-878
Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
The aim was to determine the cost effectiveness of secukinumab, a fully human interleukin-17A inhibitor, for adults in the UK with active psoriatic arthritis (PsA) who are tumour necrosis factor inhibitor (TNFi) naïve and without concomitant moderate-to-severe psoriasis, and who have responded inadequately to conventional systemic disease-modifying anti-rheumatic drugs (csDMARDs).
- 25 May 2018
- Published by Springer Nature in PharmacoEconomics
- Vol. 36 (7) , 867-878
Open AccessCost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
The aim was to determine the cost effectiveness of secukinumab, a fully human interleukin-17A inhibitor, for adults in the UK with active psoriatic arthritis (PsA) who are tumour necrosis factor inhibitor (TNFi) naïve and without concomitant moderate-to-severe psoriasis, and who have responded inadequately to conventional systemic disease-modifying anti-rheumatic drugs (csDMARDs).
- Open Access
- 24 June 2017
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 32 (1) , e5-e6
Measuring the societal impact of psoriasis in the United Kingdom through a non-interventional study of patients
- 24 June 2017
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 32 (1) , e5-e6
Open AccessMeasuring the societal impact of psoriasis in the United Kingdom through a non-interventional study of patients
- Open Access
- 21 April 2017
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 56 (suppl_2)
107. LONG-TERM EFFICACY OF SECUKINUMAB CONDITIONAL ON RESPONSE STATUS AT WEEK 12: ANALYSIS IN TUMOUR NECROSIS FACTOR α INHIBITOR–NAÏVE AND TUMOUR NECROSIS FACTOR α INHIBITOR INADEQUATE RESPONDER PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS
Background: Ankylosing spondylitis (AS) is a chronic arthritic disease associated with pain and functional deterioration. Patients with active AS and an inadequate response to conventional therapy can be treated with several licensed biologic agents including tumour necrosis factor α (TNF-α) inhibitors and secukinumab, a first-in-class, fully human interleukin-17A inhibitor. However, treatment guidelines highlight the importance of assessing response to biologics after 12 weeks and only continuing treatment if there is clear evidence of response. Secukinumab has been demonstrated to significantly improve the signs and symptoms of AS in two randomized controlled trials, MEASURE 1 and MEASURE 2. This analysis aimed to assess the importance of response status at 12 weeks as an indicator of longer-term outcomes with secukinumab 150 mg in TNF-α inhibitor–naïve and TNF-α inhibitor inadequate responder (TNF-α inhibitor-IR; primary or secondary treatment failure, contraindications or intolerance).
- 21 April 2017
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 56 (suppl_2)
Open Access107. LONG-TERM EFFICACY OF SECUKINUMAB CONDITIONAL ON RESPONSE STATUS AT WEEK 12: ANALYSIS IN TUMOUR NECROSIS FACTOR α INHIBITOR–NAÏVE AND TUMOUR NECROSIS FACTOR α INHIBITOR INADEQUATE RESPONDER PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS
Background: Ankylosing spondylitis (AS) is a chronic arthritic disease associated with pain and functional deterioration. Patients with active AS and an inadequate response to conventional therapy can be treated with several licensed biologic agents including tumour necrosis factor α (TNF-α) inhibitors and secukinumab, a first-in-class, fully human interleukin-17A inhibitor. However, treatment guidelines highlight the importance of assessing response to biologics after 12 weeks and only continuing treatment if there is clear evidence of response. Secukinumab has been demonstrated to significantly improve the signs and symptoms of AS in two randomized controlled trials, MEASURE 1 and MEASURE 2. This analysis aimed to assess the importance of response status at 12 weeks as an indicator of longer-term outcomes with secukinumab 150 mg in TNF-α inhibitor–naïve and TNF-α inhibitor inadequate responder (TNF-α inhibitor-IR; primary or secondary treatment failure, contraindications or intolerance).
- Open Access
- 21 May 2016
- Published by Springer Nature in PharmacoEconomics
- Vol. 34 (8) , 815-827
Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria
Background Chronic spontaneous urticaria (CSU) negatively impacts patient quality of life and productivity and is associated with considerable indirect costs to society. Objective The aim of this study was to assess the cost utility of add-on omalizumab treatment compared with standard of care (SOC) in moderate or severe CSU patients with inadequate response to SOC, from the UK societal perspective. Methods A Markov model was developed, consisting of health states based on Urticaria Activity Score over 7 days (UAS7) and additional states for relapse, spontaneous remission and death. Model cycle length was 4 weeks, and total model time horizon was 20 years in the base case. The model considered early discontinuation of non-responders (response: UAS7 ≤6) and retreatment upon relapse (relapse: UAS7 ≥16) for responders. Clinical and cost inputs were derived from omalizumab trials and published sources, and cost utility was expressed as incremental cost-effectiveness ratios (ICERs). Scenario analyses included no early discontinuation of non-responders and an altered definition of response (UAS7 <16). Results With a deterministic ICER of £3183 in the base case, omalizumab was associated with increased costs and benefits relative to SOC. Probabilistic sensitivity analysis supported this result. Productivity inputs were key model drivers, and individual scenarios without early discontinuation of non-responders and adjusted response definitions had little impact on results. ICERs were generally robust to changes in key model parameters and inputs. Conclusions In this, the first economic evaluation of omalizumab in CSU from a UK societal perspective, omalizumab consistently represented a treatment option with societal benefit for CSU in the UK across a range of scenarios.
- 21 May 2016
- Published by Springer Nature in PharmacoEconomics
- Vol. 34 (8) , 815-827
Open AccessCost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria
Background Chronic spontaneous urticaria (CSU) negatively impacts patient quality of life and productivity and is associated with considerable indirect costs to society. Objective The aim of this study was to assess the cost utility of add-on omalizumab treatment compared with standard of care (SOC) in moderate or severe CSU patients with inadequate response to SOC, from the UK societal perspective. Methods A Markov model was developed, consisting of health states based on Urticaria Activity Score over 7 days (UAS7) and additional states for relapse, spontaneous remission and death. Model cycle length was 4 weeks, and total model time horizon was 20 years in the base case. The model considered early discontinuation of non-responders (response: UAS7 ≤6) and retreatment upon relapse (relapse: UAS7 ≥16) for responders. Clinical and cost inputs were derived from omalizumab trials and published sources, and cost utility was expressed as incremental cost-effectiveness ratios (ICERs). Scenario analyses included no early discontinuation of non-responders and an altered definition of response (UAS7 <16). Results With a deterministic ICER of £3183 in the base case, omalizumab was associated with increased costs and benefits relative to SOC. Probabilistic sensitivity analysis supported this result. Productivity inputs were key model drivers, and individual scenarios without early discontinuation of non-responders and adjusted response definitions had little impact on results. ICERs were generally robust to changes in key model parameters and inputs. Conclusions In this, the first economic evaluation of omalizumab in CSU from a UK societal perspective, omalizumab consistently represented a treatment option with societal benefit for CSU in the UK across a range of scenarios.